Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Share-based Compensation (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Share-based Compensation for 6 consecutive years, with $10.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 19.34% to $10.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $47.6 million, a 49.51% increase, with the full-year FY2025 number at $47.6 million, up 49.51% from a year prior.
  • Share-based Compensation was $10.8 million for Q4 2025 at PROCEPT BioRobotics, down from $14.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $14.5 million in Q3 2025 to a low of $650000.0 in Q1 2021.
  • A 5-year average of $5.6 million and a median of $5.0 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 269.1% in 2022, then grew 19.34% in 2025.
  • PROCEPT BioRobotics' Share-based Compensation stood at $1.5 million in 2021, then skyrocketed by 92.85% to $2.9 million in 2022, then skyrocketed by 72.65% to $5.0 million in 2023, then skyrocketed by 82.39% to $9.1 million in 2024, then rose by 19.34% to $10.8 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Share-based Compensation are $10.8 million (Q4 2025), $14.5 million (Q3 2025), and $12.2 million (Q2 2025).